Literature summary for 3.4.24.75 extracted from

Gargis, S.R.; Heath, H.E.; LeBlanc, P.A.; Dekker, L.; Simmonds, R.S.; Sloan, G.L.
Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein (2010), Appl. Environ. Microbiol., 76, 6944-6946.

Search for more literature for 3.4.24.75

Application

Application	Comment	Organism
medicine	lysostaphin has potential for use as an antistaphylococcal agent for treatment of infections caused by antibiotic-resistant strains of Staphylococcus aureus	Staphylococcus simulans

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
additional information	Staphylococcus simulans	resistance to lysostaphin is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges	?	-	?
Peptidoglycan + H2O	Staphylococcus simulans	-	Fragments of peptidoglycan	-	?

Organism

Organism	UniProt	Comment	Textmining
Staphylococcus simulans	P10547	-	-

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
additional information	resistance to lysostaphin is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges	Staphylococcus simulans	?	-	?
Peptidoglycan + H2O	-	Staphylococcus simulans	Fragments of peptidoglycan	-	?

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)